Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of people with at least one adverse effect 27/177 (15%) with almotriptan 6.25 mg 43/181 (24%) with almotriptan 12.5 mg 48/186 (26%) with almotriptan 25 mg 32/170 (19%) with placebo	P values not reported Reported as not significant for any dose of almotriptan v placebo